It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Cell motility is a critical feature of invasive tumour cells that is governed by complex signal transduction events. Particularly, the underlying mechanisms that bridge extracellular stimuli to the molecular machinery driving motility remain partially understood. Here, we show that the scaffold protein CNK2 promotes cancer cell migration by coupling the pro-metastatic receptor tyrosine kinase AXL to downstream activation of ARF6 GTPase. Mechanistically, AXL signalling induces PI3K-dependent recruitment of CNK2 to the plasma membrane. In turn, CNK2 stimulates ARF6 by associating with cytohesin ARF GEFs and with a novel adaptor protein called SAMD12. ARF6-GTP then controls motile forces by coordinating the respective activation and inhibition of RAC1 and RHOA GTPases. Significantly, genetic ablation of CNK2 or SAMD12 reduces metastasis in a mouse xenograft model. Together, this work identifies CNK2 and its partner SAMD12 as key components of a novel pro-motility pathway in cancer cells, which could be targeted in metastasis.
Cancer cell motility is necessary for cell invasion and metastasis. Here, the authors identify CNK2 as a key mediator of cancer cell motility, linking extracellular stimuli via AXL signalling and downstream activation of ARF6 GTPase, resulting in increased metastasis in preclinical models.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details




1 Université de Montréal, Institute for Research in Immunology and Cancer, Montréal, Canada (GRID:grid.14848.31) (ISNI:0000 0001 2292 3357); Université de Montréal, Molecular Biology Program, Faculty of Medicine, Montréal, Canada (GRID:grid.14848.31) (ISNI:0000 0001 2292 3357)
2 Université de Montréal, Institute for Research in Immunology and Cancer, Montréal, Canada (GRID:grid.14848.31) (ISNI:0000 0001 2292 3357)
3 Université de Montréal, Institute for Research in Immunology and Cancer, Montréal, Canada (GRID:grid.14848.31) (ISNI:0000 0001 2292 3357); Université de Montréal, Molecular Biology Program, Faculty of Medicine, Montréal, Canada (GRID:grid.14848.31) (ISNI:0000 0001 2292 3357); Université de Montréal, Department of Pharmacology and Physiology, Faculty of Medicine, Montréal, Canada (GRID:grid.14848.31) (ISNI:0000 0001 2292 3357)
4 Université de Montréal, Institute for Research in Immunology and Cancer, Montréal, Canada (GRID:grid.14848.31) (ISNI:0000 0001 2292 3357); Université de Montréal, Molecular Biology Program, Faculty of Medicine, Montréal, Canada (GRID:grid.14848.31) (ISNI:0000 0001 2292 3357); Université de Montréal, Department of Pathology and Cell Biology, Faculty of Medicine, Montréal, Canada (GRID:grid.14848.31) (ISNI:0000 0001 2292 3357)